India's API Exports Surpass Imports in FY25 Amidst Self-Reliance Drive

India's Active Pharma Ingredient (API) exports hit Rs 41,500 crore last fiscal year, exceeding imports of Rs 39,215 crore. This milestone reflects the government's successful push for a self-reliant economy, primarily through the Production Linked Incentive (PLI) scheme. The initiative strategically aims to reduce reliance on imports, particularly from China, bolstering domestic manufacturing and contributing to a positive trade balance in the pharmaceutical sector.

India has marked a significant achievement in its pharmaceutical sector, with Active Pharma Ingredient (API) exports reaching Rs 41,500 crore in the last fiscal year (FY25), successfully outperforming imports which stood at Rs 39,215 crore. This positive trade balance highlights a crucial step towards national self-reliance in the critical pharmaceutical industry. The impressive growth in exports is largely attributed to the Indian government's strategic initiatives, most notably the Production Linked Incentive (PLI) scheme. This program is specifically designed to encourage domestic manufacturing of APIs and reduce the country's historical dependence on foreign suppliers, especially China. By incentivizing local production, the PLI scheme aims to strengthen India's pharmaceutical supply chain, enhance drug security, and create a more robust domestic industrial base. The government's continued focus on 'Atmanirbhar Bharat' (Self-Reliant India) in the pharma sector is yielding tangible results, positioning India as a more formidable player in the global pharmaceutical landscape and mitigating potential vulnerabilities associated with import reliance.